Clinuvel Pharmaceuticals Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Philippe Jacques Wolgen
- Full Time Employees
- 100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 535 Bourke Street Melbourne VIC Australia 3000
- IPO Date
- Jan 30, 2008
- CIK
- 0001290877
- Website
- clinuvel.com
- Similar Companies
- Business
- Clinuvel Pharmaceuticals Limited is a global specialty pharmaceutical company focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and acute disorders affecting the skin and brain. The company offers core products including SCENESSE (afamelanotide), a first-in-class drug approved to prevent phototoxicity in adult patients with erythropoietic protoporphyria (EPP); PRÉNUMBRA, an afamelanotide immediate and modified-release formulation for expanded patient needs; and NEURACTHEL, an adrenocorticotropic hormone (ACTH)-based treatment aimed at addressing underserved patient populations. Clinuvel also develops additional melanocortin products as part of its dermatological and systemic therapeutic portfolio. The company operates globally with a focus on precision medicine and targeted therapies. Founded in 1999 and headquartered in Melbourne, Australia, Clinuvel Pharmaceuticals has recently prioritized its clinical development resources toward three strategic programs: vitiligo, ACTH therapies, and porphyrias. This rationalization aims to optimize the use of its accumulated resources and accelerate the advancement of these high-potential programs. In the past 1-2 years, Clinuvel has undertaken operational changes to focus on these three core areas, reinforcing its existing portfolio with continued development of SCENESSE and its afamelanotide-based products, as well as expanding into ACTH therapies to diversify treatment options. Additionally, Clinuvel is preparing to upgrade its American Depository Receipt (ADR) program to Level II, targeting a listing on Nasdaq expected by the end of 2025 to broaden access to U.S. capital markets. Clinuvel serves patient populations with rare and severe conditions, primarily in the dermatology and systemic disorder sectors, targeting markets in Australia, Europe, the United States, and other regions through direct commercial operations and strategic partnerships. With a strong focus on research and development, the company continues to grow its product pipeline and expand its clinical program reach in key therapeutic areas. Clinuvel's financial profile reflects robust revenue generation and profitability, supported by its specialized pharmaceutical offerings and strategic operational focus. Overall, Clinuvel Pharmaceuticals is positioned as a leading biopharmaceutical innovator specializing in niche treatments for complex disorders, leveraging melanocortin science and ACTH-based therapeutics to address unmet medical needs worldwide. Its recent strategic shifts and global expansion initiatives signal a focused drive to enhance patient outcomes and shareholder value.
CLINUVEL's ADS to commence trading on Nasdaq
SCENESSE® approved for EPP in Canada
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2026 Earnings Call Transcript
Clinuvel Pharmaceuticals Limited (CLVLY) Shareholder/Analyst Call Transcript
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
Clinuvel Pharmaceuticals Limited (CLVLY) Q4 2025 Earnings Call Transcript
CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
Clinuvel Introduces Groundbreaking Vitiligo Program at the World's Biggest Dermatology Meeting, AAD 2025
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2025 Earnings Call Transcript
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
Afamelanotide in fair-skinned Parkinson's patients
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
Malibu shines a light on CLINUVEL's pioneering work in photomedicine
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2022 Results - Earnings Call Transcript
CLINUVEL expands DNA Repair Program
Clinuvel publishes its long-awaited Strategic update